. Author manuscript; available in PMC: 2022 Feb 7.

Published in final edited form as: Clin Sci (Lond). 2020 Apr 30;134(8):961–984. doi: 10.1042/CS20190266

Table 1:

Human placental omics studies in maternal obesity.

Clinical Characteristics of Study Subjects	Tissue Type	Gestational Age/ Delivery Mode	Omics Approach
Proteins and Metabolites
Normal BMI	Placental tissue	Term; C/S	Proteome (253)
Obese (Normoglycemic) and normal BMI	Placental biopsies	Term; C/S	Metabolome (GC-MS) (136)
mRNA and miRNA
Obese, overweight, and normal BMI	Placental tissue	Term	Microarray (254)
Obese and normal BMI	Placental tissue	Term	Microarray (133)
Obese and normal BMI	Isolated primary trophoblasts	7-12 weeks; elective termination	Microarray (138)
GDM, obese, and normal BMI	Isolated trophoblast	Term; C/S	Laser microdissection prior to microarray (139)
Obese and normal BMI	Placental tissue	Term	RNAseq (137)
Obese and normal BMI	Placental tissue and placental microbiome	Term	RNAseq and 16S-seq (130)
Non-diabetic women delivering large for gestational age infants	Placental tissue	Term	lncRNA and mRNA Array (255)
DNA methylation
Obese and normal BMI	Villus tissue	Term; C/S	Methylation MeDIP/hMeDIP (144)
Obese, GDM, pre-eclamptic, and normal BMI	Placental tissue	Term	Methylation (143)
Overweight/obese (BMI>25) and normal BMI	Placental tissue	Term	Methylation, Unpublished: GSE120062

Normal BMI defined as BMI<25. GDM, Gestational Diabetes; C/S Cesarean Section; GC-MS, Gas Chromatography-Mass Spectrometry; lncRNA, long non-coding RNAs; MeDIP/hMeDIP, Methy/ 5-hydroxymethylcytosine DNA Immunoprecipitation.